Global ADHD market set to grow at a CAGR of 8% to 2018

The global attention deficit hyperactivity disorder (ADHD) therapeutics market was valued at $3.86 billion in 2010, according to a new report from GlobalData, which forecasts this to expand at a compound annual growth rate (CAGR) of 8.0% over the next eight years, to reach $7.11 billion by 2018.

Between 2005 and 2010 three drugs, namely Daytrana (methylphenidate; originated by Shire but divested to Noven Pharma last summer), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine), both from Shire, were approved in the USA. Vyvanse has a comparatively lesser potential to cause habituation and drug abuse, this has resulted in high acceptance of Vyvanse in the USA despite its high treatment cost in comparison with the existing therapies. In 2009, the authorized generic versions of Shire’s Adderall XR (mixed amphetamine salt) were launched, which resulted in a decline in the US market, in turn triggering a decline in the global ADHD market in 2009.

Geographical variations in growth